COMP360 psilocybin
Preclinical
COMPASS PathwaysCOMP360 psilocybin is one of 4 therapeutic programs targeting PTSD - Post Traumatic Stress Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in PTSD - Post Traumatic Stress Disorder
#DrugCompanyPhaseTrials
1Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
D-Cycloserine
MMassachusetts General Hospital
Phase 2
COMP360 psilocybin
COMPASS PathwaysPreclinical
Dexmedetomidine /kg/h
UUniversity Hospital Dubrava
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for COMP360 psilocybin. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company